0

CEFOBID از شرکت PFIZER

تصویر پیدا نشد !

اطلاعات داروی نمایش داده شده مستقیما از دیتابیس اطلاعات دارویی سازمان غذا و دارو آمریکا (FDA) استخراج می شود و مرتبا به روز رسانی می شود
داروی نمایش داده شده مورد تایید FDA می باشد و اطلاعات ثبت آن در زیر قابل مشاهده است

CEFOBID از شرکت PFIZER

New Drug Application (NDA): 050551

Company: PFIZER

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
CEFOBID CEFOPERAZONE SODIUM EQ 1GM BASE/VIAL INJECTABLE;INJECTION Discontinued

None

No No
CEFOBID CEFOPERAZONE SODIUM EQ 2GM BASE/VIAL INJECTABLE;INJECTION Discontinued

None

No No
CEFOBID CEFOPERAZONE SODIUM EQ 10GM BASE/VIAL INJECTABLE;INJECTION Discontinued

None

No No
Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
11/18/1982 ORIG-1 Approval

Type 1 – New Molecular Entity

STANDARD

Label is not available on this site.

Supplements
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
09/18/2020 SUPPL-46 Labeling-Package Insert

Label (PDF)

Letter (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050551s046lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/050551Orig1s046ltr.pdf

09/28/2017 SUPPL-45 Labeling-Package Insert

Label (PDF)

Letter (PDF)

Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050551s045lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/050551Orig1s045ltr.pdf

06/18/2018 SUPPL-44 Labeling-Package Insert

Label (PDF)

Letter (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050551s044lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/050551Orig1s044ltr.pdf

03/18/2015 SUPPL-43 Labeling-Package Insert

Label (PDF)

Letter (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050551s043lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/050551Orig1s043ltr.pdf

12/18/2002 SUPPL-42 Labeling

Label (PDF)

Letter (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/50551slr042_Cefobid_lbl.pdf

https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/50551slr042ltr.pdf

12/07/2001 SUPPL-41 Manufacturing (CMC)-Control

Label is not available on this site.

10/28/1994 SUPPL-40 Labeling

Label is not available on this site.

09/29/1988 SUPPL-38 Labeling

Label is not available on this site.

03/05/1990 SUPPL-19 Labeling

Label is not available on this site.

Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
Patient Package Insert
Note Url
09/18/2020 SUPPL-46

Labeling-Package Insert

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050551s046lbl.pdf
06/18/2018 SUPPL-44

Labeling-Package Insert

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050551s044lbl.pdf
09/28/2017 SUPPL-45

Labeling-Package Insert

Label (PDF)

Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050551s045lbl.pdf
03/18/2015 SUPPL-43

Labeling-Package Insert

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/050551s043lbl.pdf
12/18/2002 SUPPL-42

Labeling

Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/50551slr042_Cefobid_lbl.pdf
برچسب‌ها:

نظرات کاربران